Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Depression Market Forecast

REPORTLINKER.COM
Posted on: 22 Mar 12

PR Newswire

NEW YORK, March 22, 2012

NEW YORK, March 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Depression Market Forecasthttp://www.reportlinker.com/p0360304/Depression-Market-Forecast.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=PathologyNew product launches across the seven major markets will see the market expand incrementally to 2020, reinforcing the depression market's status as one of the largest of the CNS disorders. Lu AA21004 (Lundbeck/Takeda) will become the highest-selling drug, after negative clinical trial data for TC-5214 (Targacept/AstraZeneca) and the discontinuation of Valdoxan (agomelatine; Servier) in the US.Access Datamonitor's patient-based depression market forecast in the seven major markets, with transparent methodology and clear assumptions.Evaluate a highly granular forecast with sales value and volume projections to 2020 at the country, class, product, and regimen level.Understand depression market dynamics, and which factors will lead to commercial success.Review the products Datamonitor forecasts to launch over the next ten years, and how each subsequent launch will shape the market.Datamonitor forecasts the seven major depression markets to grow to $12.0bn by 2020 at a compound annual growth rate of 0.9%. This incremental growth is expected to come from uptake of new product launches and will offset increasing generic erosion of the market value.By 2020, sales of the leading depression drug classes, such as the SSRI and SNRI antidepressants, are expected to decline. Conversely, sales of non-traditional antidepressants are projected to rise from $1.4bn in 2010 to $3.5bn in 2020.Sales of currently marketed products are forecast to decrease three-fold over 2010–20, as the saturation of the depression market with generics increases. Nevertheless, Datamonitor expects new pipeline drugs to capture a sizable share of the market, with predicted total sales of $3.9bn in 2020 equating to a market share of 24.3%.Which products stand to benefit from the expected failure of TC-5214 to reach the market?What are the implications to the US market following Novartis's discontinuation of agomelatine development?What degree of commercial success does Datamonitor forecast for key pipeline drugs?What will the overall depression market dynamics be over the next 10 years?How will sales of the major drug classes in depression evolve during the forecast period?OVERVIEWSummaryOVERVIEWThis product contains forecasts for depression drugs across the seven major markets from 2010 to 2020. It has been designed for delivery in an excel data pack format, but for more detail about depression please see the accompanying Market and Product Forecasts: Depression word document and PowerPoint executive presentation (HC00076-003).The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative. Please select the data pack option from the download menu at the side of the page to access the model.IntroductionFeatures and benefitsResearch and analysis highlightsKey questions answeredForecasting MethodologyDisclaimerFIGURESFigure: Patient-based forecast methodology for depression, 2011Companies mentioned Hutchison 3G UK LimitedTo order this report:Pathology Industry: Depression Market ForecastMore  Market Research ReportCheck our  Industry Analysis and Insights 

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

 

SOURCE Reportlinker

PR Newswire
http://www.prnewswire.co.uk/

Last updated on: 22/03/2012

Advertising